(19)
(11) EP 4 539 873 A2

(12)

(88) Date of publication A3:
21.12.2023

(43) Date of publication:
23.04.2025 Bulletin 2025/17

(21) Application number: 23732500.6

(22) Date of filing: 13.06.2023
(51) International Patent Classification (IPC): 
A61K 39/00(2006.01)
A61P 35/00(2006.01)
 A61K 35/17(2025.01)
(52) Cooperative Patent Classification (CPC):
A61K 2300/00; A61P 35/00; A61K 2239/38; A61K 2039/58; A61K 2039/545; C07K 16/30; C07K 16/2818; A61K 2239/57; A61K 40/11; A61K 40/42
(86) International application number:
PCT/EP2023/065713
(87) International publication number:
WO 2023/242153 (21.12.2023 Gazette 2023/51)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 14.06.2022 EP 22178787

(71) Applicant: CuraCell Germany GmbH
69117 Heidelberg (DE)

(72) Inventor:
  • WINQVIST, Ola
    756 53 Uppsala (SE)

(74) Representative: Aera A/S 
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen K
1153 Copenhagen K (DK)

   


(54) DOSAGE REGIMEN COMPRISING ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES AND A CHECKPOINT INHIBITOR